Invitrogen™ CD39 Monoclonal Antibody (eBioA1 (A1)), NovaFluor™ UV 765

Description

Description: The eBioA1 monoclonal antibody reacts with human CD39 also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1) or NTPDase. Recently, CD39 and CD73 have been found on regulatory T cells (Treg). Expression of CD39 on Treg may facilitate their entry into inflamed areas where high levels of ATP are present. Expression of CD39 on Foxp3+CD4+ cells ranges from 25-45%. This product contains 1 vial of NovaFluor conjugate and 1 vial of CellBlox Plus Blocking Buffer. Applications Tested: This eBioA1 (A1) antibody has been pre-titrated and tested flow cytometric analysis of normal human peripheral blood cells. his can be used at 5 μL (0.4 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test Master mixes.

CD39 is an integral membrane protein characterized by two transmembrane domains and forms a homotetramer structure. It is recognized as the most prominent ectoenzyme within the immune system, primarily functioning to remove toxic extracellular ATP by converting it into ADP or AMP. CD39 works in conjunction with CD73 to hydrolyze ATP and is well characterized on Langerhans cells. Originally identified on activated lymphocytes, CD39 is expressed on a variety of immune cells, including peripheral blood B cells, monocytes, and T cell clones. It is also found on a subset of T cells, B cells, and dendritic cells, with weaker expression observed on monocytes and granulocytes. The CD39 cell surface antigen is a 70-100kD molecule, and its expression is induced on T cells and increases on B cells as a late activation antigen. CD39 possesses intrinsic ecto-ATPase activity, playing a crucial role in modulating extracellular nucleotide levels and contributing to immune regulation.